Scholars Central

Conference abstract

Systemic vaccination with a tuberculosis subunit vaccine leads to a better containment of the bacterial load in lung of mice treated with retinoic acid

Authors: Silvia Vendetti, Antonella Riccomi, Valentina Gesa, Elisa Cirelli, Else Marie Agger, Giovanni Piccaro, Carla Palma

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The vast majority of pathogens invade through or cause disease at mucosal surfaces. Development of novel immunization strategies suitable for mucosal vaccines is widely desired to protect against infectious diseases. However, very few mucosal vaccines are available for human use, none of which are recombinant proteins or subunits of pathogens, owing to the lack of potent and safe mucosal adjuvants. Therefore, novel approaches to elicit mucosal immune responses are highly needed. Given the crucial role of Vitamin A metabolites, such as retinoic acid (RA) in imprinting a mucosal homing capacity on T and B cells, we evaluated the capacity of RA to improve mucosal vaccinations against tuberculosis. We found that mice treated with RA as compared with untreated ones, showed enhanced mucosal (IgA) H56 mycobacterial fusion protein-specific antibody responses and enhanced Ag-specific CD4+ T lymphocytes harbouring the lung after systemic immunization with the TB subunit vaccine (CAF01 and H56). Therefore, we evaluated the effects of RA on protection against challenge with virulent Mycobacterium tuberculosis (Mtb) strain after systemic vaccination with the TB subunits vaccine (CAF01 and H56). Vaccination with BCG was included in the experiment as control. We found that immunization with CAF01 and H56 in presence of RA leads to a lower bacterial colonization in the lungs 14 days after challenge as compared to control mice. Furthermore, higher pro-inflammatory cytokine production, such as IFNγ and IL-17 was found in the lung of mice immunized with CAF01 and H56 in presence of RA 24h after Mtb infection. Therefore, we hypothesize that the mucosal immune responses elicited during vaccination in presence of RA could have an impact on the containment of bacterial growth in the lungs. This approach can contribute to progress beyond the state of the art in adjuvant research by achieving mucosal immunity in the absence of mucosal adjuvants.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Vaccines & Vaccination.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Vaccines & Vaccination
  • SubjectVaccines & Immunisation
  • BylineArticles whose byline prints “Silvia Vendetti”
  • BylineArticles whose byline prints “Antonella Riccomi”
  • BylineArticles whose byline prints “Valentina Gesa”
  • BylineArticles whose byline prints “Elisa Cirelli”
  • BylineArticles whose byline prints “Else Marie Agger”
  • BylineArticles whose byline prints “Giovanni Piccaro”
  • BylineArticles whose byline prints “Carla Palma”